Awakn Life Sciences Announces the Addition of Renowned Substance Addiction Researcher Professor Barbara Mason to Its Clinical Advisory Board
Toronto, Ontario--(Newsfile Corp. - July 22, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing and delivering medicines to better treat Addiction, is delighted to announce today that Professor Barbara Mason has joined as an advisor on Awakn's Clinical Advisory Board.
- Toronto, Ontario--(Newsfile Corp. - July 22, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing and delivering medicines to better treat Addiction, is delighted to announce today that Professor Barbara Mason has joined as an advisor on Awakn's Clinical Advisory Board.
- Prof. Mason will join the Clinical Advisory Board which, Prof. David Nutt, Dr. Ben Sessa, Prof. Celia Morgan, Ann Mithoefer, Dr. Michael Mithoefer and Prof. Matt Johnson all currently sit on.
- Professor Nutt commented; Professor Mason is another world-leading addition to an already stellar scientific advisory board.
- About Awakn Life Sciences Corp.
Awakn Life Sciences is a biotechnology company with clinical operations, researching, developing, and delivering medicine to better treat Addiction.